Docetaxel-estramustine in high-risk localized prostate cancer: First results of the French Genitourinary Tumor Group phase III trial (GETUG 12).
Karim Fizazi(Université de Lille), Stéphane Culine(Hôpital Saint-Louis), Jean Laurent Ichanté, Marjorie Baciuchka, I. Krakowski, Frank Priou, Nadine Houédé(Inserm), Gwénaëlle Gravis(Centre National de la Recherche Scientifique), Muriel Habibian, Pierre Kerbrat(Aarhus University Hospital), F. Lesaunier, J. Bérille(Regional Cancer Center), Christine Théodore(Hôpital Foch), A. Laplanche(Novartis (Switzerland)), J L Davin, Jean François Berdah, R. Delva, F. Rolland(Institut de Cancérologie de l'Ouest), J-M Ferrero(Centre Antoine Lacassagne), Loı̈c Mourey
Cited by 9
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k